Dexcom crushed earnings with a 15% EPS beat and raised full-year guidance as positive results from its CONNECT trial opened a ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, Dexcom, Inc.
MarketBeat on MSN
Dexcom Q2 earnings call highlights
Key Points Interested in DexCom, Inc.? Here are five stocks we like better. DexCom's Q2 revenue rose 13% year over year to $1 ...
GlobalData on MSN
Dexcom tweaks full-year outlook after reporting 13% growth in Q2
Following the release of its Q2 results on 30 July, Dexcom's company’s shares on the Nasdaq rose over 8% to $81.04 at market open on 31 July.
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results